CompletedNot Applicable

Stomach Cancer Exosome-based Detection

United States, Japan809 participantsStarted 2023-03-15

Plain-language summary

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histological diagnosis of stage I, II, III, IV gastric cancer (TNM classification, 8th edition) (cases). * Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment. * Confirmed cancer-free status at the time of study inclusion (Non-disease controls). Exclusion Criteria: * Lack of written informed consent. * Systemic therapy before sampling. * Synchronous gastric and non-gastric cancer diagnosed at or before surgery.

What they're measuring

Sensitivity

Timeframe: Through study completion, an average of 1 year

Trial details

NCT IDNCT06342427

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-15

View on ClinicalTrials.gov More Gastric Cancer trials